2月9日港股创新药ETF（513120）份额减少3650.00万份

Group 1 - The Hong Kong Innovative Drug ETF (513120) increased by 1.03% on February 9, with a trading volume of 3.646 billion yuan [1] - The fund's shares decreased by 36.5 million, bringing the total shares to 20.21 billion, with an increase of 982 million shares over the last 20 trading days [1] - The latest net asset value of the fund is 25.98 billion yuan [1] Group 2 - The performance benchmark for the Hong Kong Innovative Drug ETF is the return rate of the CSI Hong Kong Innovative Drug Index (denominated in RMB) [1] - The fund is managed by Guangfa Fund Management Co., Ltd., with Liu Jie as the fund manager [1] - Since its establishment on July 1, 2022, the fund has returned 28.54%, while the return over the past month is -5.38% [1]